Matthew D. Dun

Associate Professor, NHMRC Investigator, Emergint Leader 1, University of Newcastle and Hunter Medical Research Institute
  • University of Newcastle and Hunter Medical Research Institute
  • Australia

About Matthew D. Dun

I am an Australian National Health and Medical Research Council (NHMRC) Investigator, and Defeat DIPG Chadtough New Investigator. My work couples cancer cell biology with high-resolution quantitative phosphoproteomics to develop or improve treatment strategies for children diagnosed with high-risk leukaemias and high-grade gliomas. My team the 'Cancer Signalling Research Group' is situated at the University of Newcastle (UON) and the Hunter Medical Research Institute (HMRI). In 2018, my wife, brother, brother-in-law and a few very good friends started a charity 'RUN DIPG' to advocate and help change the outcomes for children diagnosed with the most lethal of all children's cancers, diffuse intrinsic pontine glioma (DIPG). Our charity was started when my then 2 year old daughter Josephine was diagnosed with DIPG. Struck by the lack of scientific knowledge – and the stark absence of treatments for DIPG patients – I created my own program of DIPG research. Our endeavours have led to the first high-resolution, quantitative proteomic analysis of the disease, which will help us better understand this condition and improve outcomes for patients. My team and I also identified the PI3K inhibitor 'Paxalisib' for the treatment of DIPG, helping it to start clinical trials and receive FDA rare disease indication in 2020. We lost Josie, nearly 2 years after diagnosis in December 2019, a harrowing journey, something no child or parent should ever have to endure, hence our/my determination to change outcomes. I am a proud dad to Josephine, George, Harriet and Henri, leaving not much time for anything else, but when I get the chance, of course I run, which poses it's own challenges as I am a 40 something ex-rugby union playing forward, with a gold frequent flyer membership to the orthopaedic surgery wing of our local hospital. I also play guitar, surf and enjoy my emerging garden.

Intro Content

Contributor Leukemia

Phosphoproteomic profiling in leukaemia illuminates treatment targets that are invisible to genomics, but how do we bring them to the clinic...

In our paper "Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in AML" we identify treatment targets invisible to genomics-based approaches. Herein, I discuss the pipelines we employed and my perspectives on how we get phosphoproteomics into the clinic.


Channels contributed to:

Behind the Paper